Metabolic shift towards oxidative phosphorylation reduces cell density-induced cancer stem cell-like characteristics in prostate cancer in vitro.
Hung Wei LaiMoe KasaiShinkuro YamamotoHideo FukuharaTakashi KarashimaAtsuhi KurabayashiMutsuo FurihataKazuhiro HanazakiKeiji InoueShun-Ichiro OguraPublished in: Biology open (2023)
Numerous cancer patients undergoing conventional cancer therapies such as radiotherapy, chemotherapy and surgical tumour removal face relapses several years or even decades later. This may be due to the presence of cancer stem cells (CSCs) which survived said therapies. In this study, we aimed to uncover the relationship between cell density and CSCs, and the role of the Warburg effect in regulating CSC-like characteristics. Method: A prostate cancer cell line, PC3, was used in this study. To investigate the Warburg effect effect and CSC-like characteristics in prostate cancer, we measured the expression levels of glycolysis and OXPHOS-related genes, and performed spheroid forming, cell viability and various glycolysis and OXPHOS-assays. Results: Increase cell density caused a metabolic shift from glycolysis to OXPHOS and higher CSC-like characteristics. However, the use of dichloroacetate (DCA), an inhibitor of the Warburg effect, significantly inhibited the cell density-induced metabolic shift and CSC-like characteristics. Conclusion: Changes in cell density strongly influenced the preferred metabolic pathway of prostate cancer cells, regulating their CSC-like characteristics. It is possible that DCA, an inhibitor of the Warburg effect, could be a novel drug used to treat CSCs by distinguishing Warburg effect, preventing future cancer relapses.
Keyphrases
- prostate cancer
- cancer stem cells
- single cell
- patients undergoing
- cell therapy
- papillary thyroid
- radical prostatectomy
- emergency department
- early stage
- poor prognosis
- oxidative stress
- mesenchymal stem cells
- rectal cancer
- radiation therapy
- current status
- high throughput
- lymph node metastasis
- long non coding rna
- adverse drug